SCHEMBL2635995

SCHEMBL2635995

CCOC(=O)Cc1cccc(NC(=O)COc2cc(C(=O)OC)cc3cc(Cl)cc(Cl)c23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
MDH1 P40925 2/20 0.41
KMT2A Q03164 4/20 0.41
LMNA P02545 3/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 2/20 0.40
TSHR P16473 1/20 0.40
MAPT P10636 4/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
TP53 P04637 2/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 2/20 0.39
MAPK1 P28482 1/20 0.39
NR4A1 P22736 1/20 0.39
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12004284 0.88 MAPT (0.49) SMN1; SMN2MDH1KMT2ALMNAALDH1A1
SCHEMBL2635615 0.88 L3MBTL1 (0.46) L3MBTL1SMN1; SMN2MDH1KMT2ALMNA
SCHEMBL2635692 0.87 RAB9A (0.44) SMN1; SMN2MDH1KMT2ALMNAHTT
SCHEMBL2635608 0.85 MAPT (0.43) SMN1; SMN2KMT2ALMNAALDH1A1TSHR
SCHEMBL2635618 0.84 NPC1 (0.39) L3MBTL1SMN1; SMN2KMT2AHTTALDH1A1
SCHEMBL2636103 0.83 SMN1; SMN2 (0.46) L3MBTL1SMN1; SMN2KMT2ALMNAHTT
SCHEMBL2635555 0.83 MAPT (0.52) L3MBTL1SMN1; SMN2KMT2ALMNAHTT
SCHEMBL2636074 0.83 NPC1 (0.55) L3MBTL1SMN1; SMN2KMT2AALDH1A1MAPT
SCHEMBL2635847 0.82 GAA (0.42) L3MBTL1LMNAALDH1A1TSHRMAPT
SCHEMBL2635233 0.81 MEN1 (0.49) SMN1; SMN2KMT2ALMNAALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 L3MBTL1 1436/4885SMN1; SMN2 508/4885MDH1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.